Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 13, 2026, NDA 204441 (Jynarque), held by Otsuka, was first approved by FDA on Apr 23, 2018, with 9 approved supplements and 0 published complete response letters.
First approved: Apr 23, 2018
Review: Priority
Supplements approved: 9
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
